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Abstract 
During the past two decades, a variety of serum or cerebrospinal fluid (CSF) 
biochemical markers in daily clinical practice have been recommended to 
diagnose and monitor diverse diseases or pathologic situations. It will be 
essential to develop a panel of biomarkers, to be suitable for evaluation of 
treatment efficacy, representing distinct phases of injury and recovery and 
consider the temporal profile of those. Among the possible and different 
biochemical markers, S100b appeared to fulfill many of optimized criteria of 
an ideal marker. S100b, a cytosolic low molecular weight dimeric calcium-
binding protein from chromosome 21,  synthesized in glial cells throughout 
the CNS,  an homodimeric diffusible, belongs to a family of closely related 
protein, predominantly expressed by astrocytes and Schwann cells and a 
classic immunohistochemical marker for these cells, is implicated in brain 
development and neurophysiology. Of the 3 isoforms of S-100, the BB 
subunit (S100B) is present in high concentrations in central and peripheral 
glial and Schwann cells, Langerhans and anterior pituitary cells, fat, muscle, 
and bone marrow tissues. The biomarker has shown to be a sensitive marker 
of clinical and subclinical cerebral damage, such as stroke, traumatic brain 
injury, and spinal cord injury. Increasing evidence suggests that the biomarker 
plays a double function as an intracellular regulator and an extracellular signal 
of the CNS. S100b is found in the cytoplasm in a soluble form and also is 
associated with intracellular membranes, centrosomes, microtubules, and type 
III intermediate filaments.  Their genomic organization now is known, and 
many of their target proteins have been identified, although the mechanisms 
of regulating S100b secretion are not completely understood and appear to be 
related to many factors, such as the proinflammatory cytokines, tumor 
necrosis factor alpha (TNF-a), interleukin (IL)-1b, and metabolic stress. 
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According to the recently published Global 
Burden of Disease Study (1), cerebrovascular diseases 
are the second leading cause of death globally and the 
third leading cause of premature death and disability 
as measured in Disability-adjusted life years (DALY) 
(2, 3). According to a study conducted by the World 
Economic Forum, the lost economic output from 
cerebrovascular diseases (such as ischemic, 
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hemorrhagic, and other non-ischemic strokes), 
chronic respiratory disease, cancer, and diabetes in 
low and middle income countries is estimated to 
exceed USD $7 trillion over the period 2011–2025 (4) 
that often result in long-term disability for survivors 
(3). When these cerebrovascular attacks persist for a 
few minutes, cerebral oxygenation levels become 
significantly decrease and brain cells begin to die, 
after a lapse of five minutes, permanent hypoxic brain 
injury ensues, can lead to permanent and severe 
disabilities.  
Considering the fact, early diagnosis and 
treatment of acute cerebral vascular disease is a 
paramount important matter in clinical practice (5). 
Currently, computed tomography (CT) 
perfusion imaging and digital subtraction angiography 
are frequently applied to evaluate hemodynamic 
changes and to visualize lesions in patients with acute 
cerebral vascular disease (6); moreover, with the 
development of CT software and hardware 
technology, multi-slice spiral CT has become an 
important diagnostic method for ischemic cerebral 
stroke because of its low cost, high accuracy, and ease 
of operation; however, CT perfusion imaging alone 
has some deficiencies in the diagnosis of acute 
ischemic cerebrovascular diseases and it is not 
accessible in each hospital and caring center. 
Furthermore, according to the paramount important 
role of early diagnosis and treatment of the events in 
preventing diseases' disability established according 
to the DALYs reports, some other methods like 
biomarkers are necessary to do better in fulfilling and 
covering the purpose and be accessible in urban and 
suburban areas. 
Brief Report 
Considering the issues, during the past two 
decades, a variety of serum or cerebrospinal fluid 
(CSF) biochemical markers in daily clinical practice 
have been recommended to diagnose and monitor 
diverse diseases or pathologic situations including 
cardiac arrest, anoxic and traumatic brain injury, and 
cerebrovascular accidents and diseases in 
neurocritical care (7); nevertheless, no biochemical 
markers are currently applied in clinical practice as 
diagnose or monitor markers in neurocritical care; 
although, some authors have been described a series 
of biochemical markers including neuron-specific 
enolase, TAU protein, glial fibrillary astrocytic 
protein, cell-free DNA,  adenylate kinase, creatinine 
phosphokinase isoenzyme BB, lactate, myelin basic 
protein, and S100B protein (8, 9).  
The Biomarkers Definitions Working Group 
more broadly defines a biomarker as a characteristic 
that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a 
therapeutic intervention (10).  The ideal peripheral 
biomarker will be measured noninvasively such as in 
an easily accessible biofluid including serum or urine. 
Furthermore, a panel of multiple biomarkers would 
likely have greater sensitivity and specificity than a 
single marker alone (10-13); it it while that selecting 
and introducing some optimal and suitable biomarkers 
and picking up ideal biochemical markers is highly 
important for both clinicians and patients. 
The ideal biomarker should have specific 
properties such as being  "inexpensive", "preferably 
should be performed within minutes", "have 
elimination within a few hours", "have a predictability 
of serious injury from an early sample", "should have 
rapidly and readily obtainable assay results", "should 
have rapid and significant release into blood after 
injury", "have central nervous specificity", "and 
should help clinicians in replacing advanced imaging 
in the patients' managing processes", "have high 
sensitivity and specificity, negative and positive 
predictive values, positive and negative likelihood 
ratios, and high area under the curve with the low 
standard errors in replacing the usual and unusual 
diagnostic methods", "preventing to referee  patients 
especially acute ones to first-hand centers for better 
assessment and evaluation", "relationship of marker 
concentration to the degree of injury, quantifying the 
full range from subtle deficits to gross injury", and 
finally " predicting patients' prognosis from high to 
poor with relatively exact percent's" (14); however, 
The temporal profile of a biomarker is also important 
and should be noticed as a important key 
characteristic of each biomarker. It will be essential to 
develop a panel of biomarkers representing distinct 
phases of injury and recovery for evaluation of 
treatment efficacy. Based on the timing of various 
components of the secondary injury cascade, a 
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biomarker for an early post injury time point may not 
be appropriate for a later time point. 
It would be an important development if the 
biomarkers in neurocritical care to be specific, 
standardized, and incorporated in clinical practice in 
helping clinicians in the early diagnosis of an 
evolving brain damage, monitoring and employing 
the most effective therapeutic agents. 
Therefore, review of the literatures were 
elucidated among the possible biochemical markers, 
S100b appeared to fulfill many of the above criteria 
of an ideal marker (15); because has been shown to 
have neurotrophic effects as well as mitogenic and 
morphological activity on astrocytes (14) but also 
abundant in other cell types (16).   
Protein S100β (S100β) is a 21 kDa protein with 
a biological half-life of 2.5 h. PS100 β was important 
innovation in the field of neurologic prognosis in the 
past decade. The biomarker has been described to 
increase after stroke or traumatic brain injury and is 
correlated with ongoing neurologic damage and 
prognosis (17). 
Discussion 
S100b has been suggested to play a part in a 
variety of cellular processes, primarily via binding to 
key synaptic proteins and inhibition of their 
phosphorylation (18). S100b is synthesized and 
secreted by astrocytes (19) and its extracellular form 
is physiologically implicated in the development and 
maintenance of central nervous system (CNS) 
homeostasis(16). The mechanisms of regulating 
S100b secretion are not completely understood and 
appear to be related to many factors (20, 21), such as 
the proinflammatory cytokines, tumor necrosis factor 
alpha (TNF-a), interleukin (IL)-1b (22), and 
metabolic stress (23). Moreover, a previous study 
suggested that S100b secretion involves the MAPK 
pathway and apparently could involve NF-kB 
signaling (20). Within cells, it is involved in the 
regulation of cell proliferation, differentiation, Ca2+ 
homeostasis, protein phosphorylation, transcription, 
enzyme activity and metabolism. When secreted into 
the extracellular medium, S100β exerts regulatory 
effects on neighboring cells including astrocytes, 
neurons, and microglia. At nanomolar levels, S100β 
has neurotrophic activity in the extracellular medium, 
while at micromolar levels it stimulates apoptosis 
(19). 
S100β protein, which is found at a high 
concentration in glial and Schwann cells, is 
considered to be a promising biochemical marker of 
spinal cord injury (SCI) and traumatic brain injury 
(TBI); however, serum S100β levels after 
cardiopulmonary bypass (CPB) are influenced by 
extracerebral contamination, increased permeability 
of the blood-brain barrier, and impaired renal 
function;  because S100β levels in the cerebrospinal 
fluid (CSF) are unlikely to be affected by these 
responses to CPB, and CSF samples can be collected 
when CSF drainage is used, it seems reasonable to 
measure them as a marker of SCI and TBI (24). 
The results of a study clearly demonstrated that 
CSF S100β levels were significantly correlated with 
SCI and those in the SCI group peaked 48 hours after 
thoracoabdominal aortic operations. Another 
important finding is that CSF levels seem more 
reliable than serum levels because CSF S100β levels 
of the SCI group were from 10 to 100 fold higher than 
serum S100β levels (24).  
For traumatic brain injury (TBI), it is the most 
extensively studied biomarker in all severities of TBI, 
with well over 300 studies to date. S100B is the 
closest a biomarker for TBI has come to clinical use. 
In neuroimaging guidelines for adults with TBI, the 
American College of Emergency Physicians/Centers 
for Disease Control and Prevention state that “in mild 
TBI patients without significant extra-cranial injuries 
and a serum S-100B level less than 0.1μg/L measured 
within four hours of injury, consideration can be 
given to not performing a CT” while noting that 
measuring S100B levels is not an FDA approved test 
for clinical use (10, 25) . S100B has been 
implemented into clinical practice in Scandinavia 
where guidelines for the initial management of 
minimal, mild, and moderate head injury recommend 
that GCS 14–15 patients with no risk factors and a 
serum S100B b0.10 μg/L measured within six hours 
of injury be discharged without a CT scan, 
considering it a “moderate quality, strong 
recommendation”(10, 26). However, although 
acknowledging that S100B can be a sensitive 
indicator of brain injury, whether it adds value to 
clinical guidelines for TBI diagnosis has been 
Rezaeiet al.                                                                                              Biochemical Markers in Neurocritical Care 
Journal of Cellular & Molecular Anesthesia (JCMA) 
118 
questioned (10). 
The results of a study with the purposes 
determining whether elevated serum S100b correlates 
with neurologic complications in patients requiring 
hypothermic circulatory arrest (HCA) during thoracic 
aortic repair, and to determine the impact of 
retrograde cerebral perfusion (RCP) on S100b release in 
this setting, showed that serum S100b levels of 6.0 mg/L 
or higher after HCA correlates with postoperative 
neurologic complications. Using serum S100b as a 
marker for brain injury, RCP does not provide improved 
cerebral protection over HCA alone(27). 
Conclusion 
In conclusion, at the moment, it is an exciting 
time for development and exploration of a suitable 
biochemical marker in neurocritical care to play as a 
standardized and incorporated tool into routine 
clinical practice for diagnosis, determining early 
prognosis and other management aspects of 
neurocritical patients in diagnosis and detecting of 
ongoing brain damage; moreover, the markers can 
also have a helping role to define therapeutic targets 
and provide the diagnostic value in detecting, 
monitoring, and treatment efficacy of ongoing brain 
damage. Among the different biomarkers,   S-100b 
has shown to be a sensitive marker of clinical and 
subclinical cerebral damage, such as stroke, traumatic 
brain injury, and spinal cord injury.  
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